help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiley, R. E.
Right arrow Articles by Jordana, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiley, R. E.
Right arrow Articles by Jordana, M.
American Journal of Respiratory Cell and Molecular Biology. Vol. 28, pp. 722-730, 2003
© 2003 American Thoracic Society
DOI: 10.1165/rcmb.2002-0220OC

Evaluation of Inducible Costimulator/B7-Related Protein-1 as a Therapeutic Target in a Murine Model of Allergic Airway Inflammation

Ryan E. Wiley, Susanna Goncharova, Theresa Shea, Jill R. Johnson, Anthony J. Coyle and Manel Jordana

Division of Respiratory Diseases and Allergy, Centre for Gene Therapeutics, and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; and Department of Experimental Medicine, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts

Address correspondence to: Dr. Manel Jordana, Department of Pathology and Molecular Medicine, Room 4H17, Health Sciences Centre, McMaster University, 1200 Main Street West, Hamilton, ON, L8N 3Z5 Canada. E-mail: jordanam{at}mcmaster.ca

Given its primary role in the execution of T cell, and especially Th2, effector activity, the inducible costimulator (ICOS)/B7-related protein (RP)-1 costimulatory pathway is currently being heralded as a promising therapeutic target for immune-inflammatory disorders such as asthma. This study investigates the merits of ICOS blockade in a murine model of experimental asthma in which mice are sensitized to ovalbumin (OVA) through the respiratory mucosa. Intraperitoneal treatment of mice with anti-ICOS neutralizing antibody during sensitization resulted in a marked reduction in airway eosinophilia and IL-5 in bronchoalveolar lavage, but had no effect on interleukin (IL)-4, IL-13, and eotaxin content in bronchoalveolar lavage or the production of OVA-specific immunoglobulin E in serum. Cultured splenocytes from mice sensitized to OVA in the context of ICOS ablation produced enhanced levels of IL-4 and IL-5 upon stimulation with OVA, and this correlated with elevated inflammation and immunoglobulin E secretion upon long-term in vivo OVA recall; the deleterious effects ICOS blockade, however, were not associated with reduced IL-10 production by splenocytes. Peculiarly, anti-ICOS intervention during OVA rechallenge had no effect on airway inflammation or immunoglobulin production, despite high levels of ICOS expression on infiltrating CD4+ T cells. This study provides in vivo evidence of an exacerbated long-term immune-inflammatory response following acute ICOS blockade, and suggests that ICOS costimulation is functionally redundant in established allergic disease.

Abbreviations: adenovirus, Ad • B7-related protein-1, B7RP-1 • bronchoalveolar lavage, BAL • enzyme-linked immunosorbent assay, ELISA • granulocyte-macrophage colony-stimulating factor, GM-CSF • Hanks' balanced salt solution, HBSS • inducible costimulator, ICOS • immunoglobulin E, IgE • interleukin, IL • monoclonal antibody, mAb • ovalbumin, OVA • phosphate-buffered saline, PBS




This article has been cited by other articles:


Home page
LupusHome page
M Her, D Kim, M Oh, H Jeong, and I Choi
Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus
Lupus, May 1, 2009; 18(6): 501 - 507.
[Abstract] [PDF]


Home page
J. Immunol.Home page
J. M. Odegard, L. D. DiPlacido, L. Greenwald, M. Kashgarian, D. H. Kono, C. Dong, R. A. Flavell, and J. Craft
ICOS Controls Effector Function but Not Trafficking Receptor Expression of Kidney-Infiltrating Effector T Cells in Murine Lupus
J. Immunol., April 1, 2009; 182(7): 4076 - 4084.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S.-Y. Nam, Y.-H. Kim, J.-S. Do, Y.-H. Choi, H.-J. Seo, H.-K. Yi, P.-H. Hwang, C.-H. Song, H.-K. Lee, J.-S. Kim, et al.
CD30 supports lung inflammation
Int. Immunol., February 1, 2008; 20(2): 177 - 184.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
K. C. Beier, T. Kallinich, and E. Hamelmann
T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease
Eur. Respir. J., August 1, 2007; 30(2): 383 - 390.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. U. Gajewska, A. Tafuri, F. K. Swirski, T. Walker, J. R. Johnson, T. Shea, A. Shahinian, S. Goncharova, T. W. Mak, M. R. Stampfli, et al.
B7RP-1 Is Not Required for the Generation of Th2 Responses in a Model of Allergic Airway Inflammation but Is Essential for the Induction of Inhalation Tolerance
J. Immunol., March 1, 2005; 174(5): 3000 - 3005.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. R. Johnson, R. E. Wiley, R. Fattouh, F. K. Swirski, B. U. Gajewska, A. J. Coyle, J.-C. Gutierrez-Ramos, R. Ellis, M. D. Inman, and M. Jordana
Continuous Exposure to House Dust Mite Elicits Chronic Airway Inflammation and Structural Remodeling
Am. J. Respir. Crit. Care Med., February 1, 2004; 169(3): 378 - 385.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2003 American Thoracic Society.
  New Orleans Int'l Conf